Biomarkers: Their potential in the diagnosis and treatment of heart failure

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cleveland Clinic journal of medicine

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3949/ccjm.82.s2.05PMID 26694889
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure.

  2015cited by this paper
• Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

  2015cited by this paper
• Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study

  2015cited by this paper
• The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

  2015cited by this paper
• Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial.

  2015cited by this paper
• The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications.

  2015cited by this paper
• Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.

  2015cited by this paper
• Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial

  2015cited by this paper
• Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

  2014cited by this paper
• Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial

  2014cited by this paper
• Determinants and implications of elevated soluble ST2 levels in heart failure.

  2014cited by this paper
• High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial.

  2014cited by this paper
• Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

  2014cited by this paper
• Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

  2014cited by this paper
• Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

  2013cited by this paper
• Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.

  2013cited by this paper
• Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes

  2013cited by this paper
• Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study

  2013cited by this paper
• Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results.

  2013cited by this paper
• Treatment of anemia with darbepoetin alfa in systolic heart failure.

  2013cited by this paper
• Novel urinary biomarkers in detecting acute kidney injury, persistent renal impairment, and all-cause mortality following decongestive therapy in acute decompensated heart failure.

  2013cited by this paper
• Incorporating Common Biomarkers into the Clinical Management of Heart Failure

  2013cited by this paper
• Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH

  2013cited by this paper
• Association between bilirubin and mode of death in severe systolic heart failure.

  2013cited by this paper
• Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events

  2012cited by this paper
• The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

  2012cited by this paper
• Breathing not properly 10 years later: what we have learned and what we still need to learn.

  2012cited by this paper
• Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study

  2012cited by this paper
• Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials

  2012cited by this paper
• Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

  2012cited by this paper
• Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure

  2012cited by this paper
• Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study

  2012cited by this paper
• Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.

  2011cited by this paper
• High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure

  2011cited by this paper
• Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease.

  2011cited by this paper
• Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

  2011cited by this paper
• Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure

  2010cited by this paper
• Prognostic value of galectin-3, a novel marker of fibrosis

  2010cited by this paper
• Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study

  2009cited by this paper
• Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure.

  2009cited by this paper
• Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure.

  2008cited by this paper
• Impact of myocardial function on cystatin C measurements in chronic systolic heart failure.

  2008cited by this paper
• Cardiac troponin and outcome in acute heart failure.

  2008cited by this paper
• Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

  2008cited by this paper
• Incident Heart Failure Prediction in the Elderly: The Health ABC Heart Failure Score

  2008cited by this paper
• Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.

  2008cited by this paper
• Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.

  2007cited by this paper
• IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.

  2007cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure.

  2007cited by this paper
• Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.

  2007cited by this paper
• Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.

  2007cited by this paper
• Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

  2007cited by this paper
• Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure

  2006cited by this paper
• Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

  2006cited by this paper
• The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.

  2005cited by this paper
• Obesity and suppressed B-type natriuretic peptide levels in heart failure.

  2004cited by this paper
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

  2004cited by this paper
• Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

  2004cited by this paper
• Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

  2002cited by this paper

• Circular RNAs in Heart Diseases.

  2025cites this paper
• Potential Effects of Orally Ingesting Polyethylene Terephthalate Microplastics on the Mouse Heart

  2024cites this paper
• Detailed profiling of m6A modified circRNAs and synergistic effects of circRNA and environmental risk factors for coronary artery disease.

  2023cites this paper
• Effect of body mass index on N-terminal pro-brain natriuretic peptide values in patients with heart failure

  2023cites this paper
• Exploring the Multifaceted Biologically Relevant Roles of circRNAs: From Regulation, Translation to Biomarkers

  2023cites this paper
• Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure

  2022cites this paper
• The impact of polystyrene microplastics on cardiomyocytes pyroptosis through NLRP3/Caspase‐1 signaling pathway and oxidative stress in Wistar rats

  2021cites this paper
• Quantitative Expression Analysis of Circulating miRNAs Reveals Significant Association with Cardiovascular Pathogenesis in Women

  2020cites this paper
• Association of Circulating miRNAs with Cardiovascular Pathogenesis in Women

  2020cites this paper
• Definition and review on a category of long non-coding RNA: Atherosclerosis-associated circulating lncRNA (ASCLncRNA)

  2020cites this paper
• Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases

  2020cites this paper
• Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure

  2020cites this paper
• miRNAs emerge as circulating biomarkers of post-myocardial infarction heart failure

  2019cites this paper
• Serum Levels of Inflammatory Cytokines and Expression of BCL2 and BAX mRNA in Peripheral Blood Mononuclear Cells and in Patients with Chronic Heart Failure

  2019cites this paper
• Circular RNAs as potential biomarkers and therapeutics for cardiovascular disease

  2019cites this paper
• Placenta growth factor and sFlt-1 as biomarkers in ischemic heart disease and heart failure: a review.

  2019cites this paper
• Utility of a Novel Biomarker Panel in the Prediction of QT Dynamicity

  2019cites this paper
• Cerebral desaturation in heart failure: Potential prognostic value and physiologic basis

  2018cites this paper
• Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design

  2018cites this paper
• Circular RNAs as Novel Biomarkers for Cardiovascular Diseases.

  2018cites this paper
• Circular RNAs: Promising Biomarkers for Human Diseases

  2018cites this paper
• Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure

  2017cites this paper
• Upregulation of Circulating miR-195-3p in Heart Failure

  2017cites this paper
• Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure

  2016cites this paper
• miR-218 Involvement in Cardiomyocyte Hypertrophy Is Likely through Targeting REST

  2016cites this paper
• Molecular and Digital Biomarker Supported Decision Making in Clinical Studies in Cardiovascular Indications

  2016cites this paper
• Biomarkers in Heart Failure, Use of

  2014cites this paper